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Strict implementation of guidelines directed at multiple
targets reduces vascular risk in diabetic patients. Whether
this also applies to patients with chronic kidney disease (CKD)
is uncertain. To evaluate this, the MASTERPLAN Study
randomized 788 patients with CKD (estimated GFR 20–70ml/
min) to receive additional intensive nurse practitioner
support (the intervention group) or nephrologist care (the
control group). The primary end point was a composite of
myocardial infarction, stroke, or cardiovascular death. During
a mean follow-up of 4.62 years, modest but significant
decreases were found for blood pressure, LDL cholesterol,
anemia, proteinuria along with the increased use of active
vitamin D or analogs, aspirin and statins in the intervention
group compared to the controls. No differences were found
in the rate of smoking cessation, weight reduction, sodium
excretion, physical activity, or glycemic control. Intensive
control did not reduce the rate of the composite end point
(21.3/1000 person-years in the intervention group compared
to 23.8/1000 person-years in the controls (hazard ratio 0.90)).
No differences were found in the secondary outcomes of
vascular interventions, all-cause mortality or end-stage renal
disease. Thus, the addition of intensive support by nurse
practitioner care in patients with CKD improved some risk
factor levels, but did not significantly reduce the rate of the
primary or secondary end points.
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Chronic kidney disease (CKD) is a known risk factor for
cardiovascular disease (CVD).1–3 This increased CVD risk is
attributed to traditional risk factors (e.g., hypertension,
dyslipidemia, diabetes, male gender, and smoking) and
kidney disease–specific risk factors such as anemia, albumi-
nuria, and calcium–phosphate disbalance.4 The contribution
of one risk factor to CVD risk is small, but a combination
results in a very high CVD risk.4,5 Despite the existence of
guidelines, studies in several high-risk groups demonstrated
that goals for treatment are often not met.6–11 The same holds
for CKD patients.12 Physicians usually do not have the
time to address all relevant issues regarding CVD risk.
Nurse practitioners may be of help. The benefits of coaching
by nurse practitioners are evident in other high-risk popula-
tions.13–15 Studies in patients with diabetes mellitus or heart
failure showed that a multifactorial intervention implemented
by nurse practitioners significantly improved metabolic
control and reduced CVD.13–15 Given the high CVD risk
and the multitude of modifiable risk factors a multifactorial
approach could also be of benefit for patients with CKD.4,5
The aim of our study was to assess whether the addition of
nurse practitioner care to standard care by a nephrologist in
patients with moderate-to-severe CKD, aimed at strict
implementation of current guidelines with emphasis on
CVD medication and lifestyle changes, improves cardiovas-
cular outcome.16
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RESULTS
About 60% of patients deemed eligible by their physician and
asked to participate in the study actually participated and
were included. Non-participation was mainly because of
reluctance to change drug therapy and inability to attend the
required visits.
Between April 2004 and December 2005 we randomized 793
patients (Figure 1). Three patients did not meet inclusion
criteria and two declined participation directly after randomi-
zation. Thus, 788 patients were included in the study:
393 in the control group and 395 in the intervention group.
Characteristics were well balanced between groups apart
from a history of CVD, which was more common, and current
smoking, which was less prevalent in the intervention group
(Table 1).
The clinical characteristics of the 110 transplant recipients
were: 59% men, 92% Caucasian, age 51 (12) years, estimated
glomerular filtration rate 40 (13) ml/min per 1.73 m2. Mean
duration after transplantation was 7.5 (5.4) years. In all,
73% used a calcineurin inhibitor, 68% used an antimetabolite
(i.e., mycophenolate or azathioprine), and 74% had steroids.
Mean follow-up duration for the entire cohort was 4.62
years (median: 4.83; interquartile range 4.44 to 5.36). Follow-
up was concluded in May 2010.
Effect on targeting risk factors
During the follow-up, mean office blood pressure (BP) was
significantly lower in the intervention group (132/77 mm Hg)
than in the control group (135/79 mm Hg). Similar differences
were found for oscillometric BP measurements (Table 2).
Significant differences were found for low-density lipoprotein
(LDL) cholesterol (0.11 mmol/l (4 mg/dl)), triglycerides
(0.15 mmol/l (13 mg/dl)), hemoglobin (þ 0.01 mmol/l)
(þ 0.02 g/dl), anemia (2%), proteinuria (0.12 g per 24 h)
and use of active vitamin D (or analogs) (þ 4.6%), aspirin
(þ 10%), and statins (þ 4.7%). The number of antihyperten-
sive drugs was higher and increased more in the intervention
arm (3.16 vs. 3.04; P¼ 0.04). Use of angiotensin-converting
enzyme inhibitors and/or angiotensin receptor blockers
showed a trend of increased use in the intervention arm
(þ 2.6%; P¼ 0.07). No differences were found for smoking,
body weight, sodium excretion, physical activity, or glycemic
control (Table 2). The magnitude of the differences was
small, despite its statistical significance (Figure 2, Table 2 and
Supplementary Figure S1 online).
In the control group, similar beneficial trends were seen,
leading to smaller differences between treatment groups. This
is illustrated for oscillometric BP measurements, lipid
lowering drugs, and for platelet aggregation inhibitors
(Figure 2). Identical patterns of changes in lifestyle factors
were observed in both treatment arms for body mass index
and smoking (Supplementary Figure S2 online).
In patients who at baseline had proteinuria 40.5 g per
24 h, mean proteinuria during follow-up in the intervention
group was 1.7 g per 24 h and in the control group 1.9 g per
24 h (P¼ 0.08).
Randomized: 793
Withdrew consent: 3
Did not meet inclusion criteria: 2
Intervention group: 395 Control group: 393
Year 1: ESRD: 8
Died: 6
Censored: 9
Year 2: ESRD: 9
Died: 9
Censored: 8 
Year 3: ESRD: 10
Died: 8
Censored: 6
Year 4: ESRD: 15
Died: 11
Censored: 15
Year 5: ESRD: 6
Died: 10
Censored: 123
Year 6: ESRD: 2
Died: 2
Censored: 141
Endpoint 
analysis: 395
Endpoint 
analysis: 393
Risk factor 
analysis: 395
Risk factor 
analysis: 393
Year 1: ESRD: 4
Died: 9
Censored: 7
Year 2: ESRD: 4
Died: 7
Censored: 16
Year 3: ESRD: 18
Died: 13
Censored: 8
Year 4: ESRD: 16
Died: 15
Censored: 16
Year 5: ESRD: 0
Died: 7
Censored: 120
Year 6: ESRD: 0
Died: 1
Censored: 120
Figure 1 | Flow chart of participants. Censored means lost to follow-up (not due to ESRD or death), because of moving to another hospital,
end of study, or failure to contact the participant. ESRD, end-stage renal disease (either dialysis or transplantation).
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Effect on end points
A total of 80 participants had a major nonfatal or fatal
CVD event during follow-up (Table 3). Intensive control did
not reduce the rate of the composite end point (21.3/1000
person-years in the intervention group vs. 23.8/1000 person-
years in the control group; hazard ratio (HR) 0.90
(95% confidence interval (CI) 0.58, 1.39, P¼ 0.63)). The
data safety monitoring board also reported their results for
the primary end point adjusted for the sequential analysis
(HR 0.84 (95% CI 0.45, 1.35), P¼ 0.48).
As history of CVD and diabetes were not distributed
equally in the two groups because of chance, an additional
analysis was performed. With adjustment for history
of CVD and baseline smoking the HR was 0.80 (95% CI
0.55–1.25).
No statistically significant differences were found in
secondary event outcomes, including end-stage renal disease
(dialysis and/or transplantation) (28.6 vs. 34.4/1000 person-
years; HR 0.83 (95% CI 0.57, 1.20), P¼ 0.32). Subgroup
analyses for baseline parameters such as age, gender, BP, baseline
estimated GFR calculated by the Modification of Diet in Renal
Disease formula, and previous CVD history showed no
heterogeneity for the composite end point (all P-values for the
interaction terms40.20). For kidney transplantation, the P-value
of the multiplicative interaction term in Cox model for the
composite end point was 0.41 and for all-cause mortality 0.16, for
a history of diabetes the P-value of the multiplicative interaction
term in Cox model for the composite end point was 0.88.
Number of visits to the outpatient clinic department
The mean number of annual outpatient clinic visits (physician
and/or nurse practitioner) during the first 2 years was
significantly higher in the intervention group than in the
control group (7.2 vs. 4.7; Po0.001). The mean number of
physician visits in the intervention group was significantly
lower than in the control group (2.8 vs. 3.7; Po0.001).
Quality of life by EQ-5D
In both intervention and control group, a gradual rise in
quality of life assessed by EQ-5D could be found. Baseline
score was 0.80 in both groups and increased to 0.83.
However, there was no difference for quality of life between
intervention and control (P¼ 0.79).
DISCUSSION
This study shows that nurse practitioner–assisted care
targeting multiple risk factors in CKD results in better BP
control and lipid management, less proteinuria and the
increased use of antihypertensives, statins, aspirin, and active
vitamin D. Lifestyle interventions are ineffective. Intensive
control has no effect on clinical outcome.
Several trials reported an improvement in CVD risk factor
management by nurse practitioner support in patients
with diabetes or otherwise high CVD risk, with particular
effect on medication-dependent risk factors, such as BP and
cholesterol.13,17–21 Our study confirms that notion.
Some other studies need to be discussed in some detail. The
first is the Steno-2 study, which served as an example for our
study. It reported not only better risk factor management, but
also a substantial improvement in clinical outcome, which
contrasts with our results. This may be explained, at least
partially, by some differences between the studies. All patients
in the Steno-2 study had type 2 diabetes, and thus another a
priori cardiovascular risk. Moreover, these patients had higher
BP and cholesterol at baseline. As a consequence, larger
improvements in BP (systolic 11 mm Hg, diastolic 4 mm Hg),
and LDL cholesterol (0.8 mmol/l (31 mg/dl)) could be
obtained. Further, the Steno investigators reported large
differences in the quality of glucose management and in the
use of aspirin between treatment arms. There is also an
important design difference between the studies. In Steno-2,
Table 1 | Characteristics of participants at baseline by
assigned treatment
Parameter
Control group
(n=393)
Intervention
group (n=395)
P-
value
Age (years) 59.3 (12.8) 58.9 (13.1) 0.60
Gender (male) (%) 68 67 0.82
Race (Caucasian) 93 91 0.65
Nephrological diagnosis (%) 0.06
Diabetic nephropathy 9 11
Renovascular 28 26
Glomerulonephritis/interstitial
nephritis
34 28
Congenital disease 13 11
Unknown 16 24
Kidney transplantation (%) 14 14 1.0
Prior cardiovascular disease by
questionnaire (%)
25 33 0.02
Creatinine (mmol/l) 181 (67) 182 (64) 0.76
eGFR (ml/min per 1.73m2)a 37.7 (14.0) 38.4 (15.2) 0.66
Office BP (mmHg) 139 (22)/81 (11) 138 (20)/80 (11) 0.90/
0.43
Oscillometric BP (mmHg) 136 (21)/79 (11) 135 (20)/78 (11) 0.46/
0.36
Proteinuria (g per 24 h)b 0.3 (0.1–0.8) 0.2 (0.1–0.8) 0.27
LDL cholesterol (mmol/l) 2.74 (0.90) 2.78 (0.95) 0.70
Hemoglobin (mmol/l) 8.2 (1.0) 8.2 (1.0) 0.88
History of DM (%)c 23 25 0.37
Phosphate (mmol/l) 1.10 (0.25) 1.11 (0.25) 0.98
PTH (pmol/l)b 9 (5–14) 9 (5–15) 0.74
Sodium excretion (mmol per
24 h)b
150 (113–189) 148 (116–195) 0.89
BMI (kg/m2) 27.2 (4.9) 27.0 (4.6) 0.53
Physical activity (%)d 60 57 0.23
Smoking (%) 24 19 0.04
Pack years (years) 6.5 (1.8–16.3) 6.3 (0–11.8) 0.13
Abbreviations: BP, blood pressure; BMI, body mass index; DM, diabetes mellitus;
eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; PTH,
parathyroid hormone.
aBased on the Modification of Diet in Renal Disease formula.
bMedian (25th–75th percentile).
cHistory of diabetes mellitus defined as using blood glucose lowering medication or
fasting glucose 47.0mmol/l.
dAdherence to Dutch physical activity guideline.
Values are proportions, means with corresponding s.d., or median with interquartile
ranges, when appropriate.
Conversion factor to mg/dl: creatinine 0.0113, LDL cholesterol 38.6, glucose 18,
phosphorus 3.1; conversion factor to g/dl: hemoglobin 1.62; conversion factor to pg/
ml: PTH 9.1.
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control patients remained in the care of a general practitioner,
whereas study patients were treated by a team led by a nurse
practitioner in a highly specialized diabetes clinic.
Two studies in CKD patients are available. A recent
randomized trial with 2 years follow-up (CanPREVENT) in
474 CKD patients compared care coordinated by nurses under
nephrologist supervision with that of general practitioners.22
They found no effect on risk factor control or on clinical end
points. However, some important differences exist between that
and our study. For instance, patients in CanPREVENT had
better preserved kidney function, less proteinuria, at baseline
already good BP control (130/74 mm Hg) and low LDL
cholesterol. Further, follow-up was limited to 2 years.
In an older study, the effects of an intensive treatment
regimen in 200 patients with CKD stage IV and V, of whom
65% were on dialysis at the start of the study, were reported.23
BP was 6.7/3.8 mm Hg and LDL cholesterol 0.4 mmol/l
(15.44 mg/dl) lower in the intervention group. After a follow-
up of 2 years, there were no differences in mortality, CVD
events or surrogate end points such as intima media thickness.
So in summary, the differences in effects on CV risk
management and clinical outcome between the various
studies may be explained by differences in patient character-
istics, design, and follow-up.
The lack of effect on lifestyle-related aspects deserves
some comment. Previous studies show benefit of a lifestyle
intervention, when targeted at a single risk factor.24–27 Recent
reports involving multiple health behavior changes usually
report no or limited effect.28–31 Our results are in line with
these studies. Also the Steno-2 study reported no beneficial
effect on weight, smoking, or physical activity.32 Only a few
studies compared the effect of single vs. multiple interven-
tions, all targeted at physical activity and nutrition.33–35 Some
showed superiority of a single intervention, whereas others
showed better results with multiple interventions.33–35 In a
recent review, it was suggested that the number of choices in
multiple interventions may overwhelm the patients.36 This
may be relevant in our study as well, because we have
formulated 11 treatment targets for our patients.
Several other issues need to be discussed when considering
the absence of a significant treatment effect in our study.
First, at the start of the study, both patients and their
physicians were informed about the existing guidelines, the
goals and aim of the study. The quality of care in the control
group also improved, as is evidenced by better BP and lipid
management and the increased use of various medications
(Figure 2). This phenomenon, which is known as contam-
ination bias, has reduced the magnitude of the differences
Table 2 | Effects of strict implementation of the guidelines on various risk factors during follow-up using the intention-to-treat
principle with complete follow-up
Mean levels at baseline Mean level during follow-upa
Risk factor Control Intervention Control Intervention Mean differencea s.e. P-value for difference
MDRD (ml/min per 1.73m2) 38.1 39.4 35.8 36.6 0.82 0.49 0.10
Systolic office BP (mmHg) 139 138 135 132 3 0.77 o0.001
Diastolic office BP (mmHg) 81 80 79 77 2 0.45 o0.001
Systolic oscillometric BP (mmHg) 136 135 132 129 3 0.61 0.002
Diastolic oscillometric BP (mmHg) 79 78 77 75 2 0.49 o0.001
LDL cholesterol (mmol/l) 2.74 2.78 2.50 2.39 0.11 0.04 0.008
HDL cholesterol (mmol/l) 1.31 1.31 1.26 1.29 0.03 0.019 0.15
Triglycerides (mmol/l) 1.89 1.80 1.89 1.74 0.15 0.06 0.009
Proteinuria (g per 24/h) 0.81 0.76 0.77 0.65 0.12 0.06 0.04
Hemoglobin (mmol/l) 8.2 8.2 8.0 8.1 0.10 0.04 0.03
Phosphate (mmol/l) 1.10 1.11 1.15 1.13 0.01 0.016 0.43
PTH (pmol/l) 11.7 10.8 13.7 13.3 0.38 0.67 0.57
HbA1c (%) 6.1 6.1 6.3 6.3 0.003 0.05 0.96
HbA1c (%) in diabetics (n=193) 6.9 6.9 7.1 7.0 0.10 0.09 0.25
BMI (kg/m2) 27.2 27.0 27.0 27.1 0.02 0.11 0.88
Sodium excretion (mmol per day) 155 156 155 156 1.15 3.12 0.72
Physical activity (%)b 60 57 58 62 3.8 2.6 0.15
Smoking (%) 24 19 14 14 0.0 0.007 0.73
No. antihypertensive drugs 3.0 2.9 3.04 3.16 0.12 0.06 0.04
Use of ACEi and/or ARB (%) 78 81 85 87 2.6 1.4 0.07
Statin use (%) 63 67 76 80 4.7 1.55 0.002
Antiplatelet drugs (%)c 39 45 57 67 9.6 2.4 o0.001
Glucose lowering drugs (%) 19 21 21 20 0.03 1.17 0.73
Vitamin D (%) 24 22 41 46 4.6 2.0 0.02
Phosphate binders (%) 13 9 18 16 1.3 1.5 0.14
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; GEE, generalized estimating
equation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease formula; PTH, parathyroid hormone.
aMean difference over time in risk factor levels between treatment arms obtained through GEE analyses using the on trial measurements with adjustments for baseline
measurements. Complete follow-up means that all individuals have been followed with respect to the risk factor measurements also when they suffered a non-fatal event or
received kidney transplant or a renal replacement therapy.
bAdherence to Dutch physical activity guideline.
cIn those not using oral anticoagulant drugs treatment at baseline.
Conversion factor to mg/dl: creatinine 0.0113, LDL cholesterol 38.6, glucose 18, phosphorus 3.1; conversion factor to g/dl: hemoglobin 1.62; conversion factor to pg/ml: PTH 9.1.
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between the two groups and therefore limits our ability to detect
differences in events rates. On the basis of the meta-analyses on
BP lowering and lipid lowering, a difference in systolic pressure
of 3.0 mm Hg could result in a 6% reduction in coronary events,
and a difference of 0.1 mmol/l in LDL in a 2% reduction
of CVD events.37,38 Our trial is not powered to detect such a
small effect size. Yet, our 95% CI around the observed effect
size includes this estimate (Table 3). We have not taken this
contamination bias in to account in our power calculation.
Second, the incidence of the primary end point is somewhat
lower than expected. This limits our ability to detect a difference
between groups. In the recent Kidney Disease: Improving Global
Outcomes CKD Prognosis Consortium analysis, the incidence
of CVD events in our study is among the lowest of the 10
included cohorts.39 Finally, recent studies have cast doubt on the
efficacy of some of our interventions. There was no benefit of
intensive BP or glucose lowering in otherwise reasonably well-
controlled patients in recent trials.40,41 As BP at baseline in our
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Figure 2 |Change in oscillometric BP (a), LDL cholesterol (b), use of statins (c) and aspirin (among those not on oral anticoagulants
at baseline) (d) in both the intervention (black symbols) and control group (white symbols) during the first 5 years of the trial.
P-value for difference between groups for systolic BP¼ 0.002; P-value for difference between groups for diastolic BP o0.001; P-value for
difference between groups for LDL cholesterol¼ 0.008; P-value for difference between groups for statins¼ 0.002; P-value for difference
between groups for aspirin o0.001; conversion factor to mg/dl: LDL cholesterol 38.6. BL, baseline; BP, blood pressure; LDL, low-density
lipoprotein; M, months.
Table 3 | Relative effects of strict implementation of the guidelines on all pre-specified primary and secondary outcomes
Control Intervention
Outcome Number of events Person-years Number of events Person-years
P-value for
difference
Hazard
ratioa
Lower
95% CI
Upper
95% CI
Compositeb 42 1767 38 1787 0.63 0.90 0.58 1.39
(Non) fatal AMI 11 1797 12 1813 0.85 1.08 0.48 2.45
(Non) fatal cerebrovascular disease 15 1781 12 1805 0.54 0.79 0.37 1.69
Fatal CV event 25 1812 23 1830 0.75 0.91 0.51 1.61
Ischemic stroke 11 1782 9 1805 0.64 0.81 0.34 1.96
All-cause mortality 52 1812 46 1830 0.52 0.88 0.59 1.30
ESRD 59 1714 50 1746 0.32 0.83 0.57 1.20
CABG 11 1784 12 1804 0.86 1.08 0.48 2.44
PTCA 16 1772 21 1790 0.40 1.30 0.68 2.50
Amputation 4 1808 6 1822 0.53 1.49 0.42 5.29
CHDplusc 31 1743 36 1761 0.57 1.15 0.71 1.86
Abbreviations: AMI, acute myocardial infarction; CI, confidence interval; CV, cardiovascular; ESRD, end-stage renal disease defined as transplantation or dialysis; CABG,
coronary artery bypass grafting; CHDplus, coronary heart disease plus; PTCA, percutaneous coronary angioplasty.
aBased on unadjusted Cox proportional hazards models using intention-to-treat principle.
bNon-fatal AMI, non-fatal stroke, fatal CV event (whatever comes first).
cNon-fatal AMI, fatal coronary event, CABG, PTCA (whatever comes first).
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study was (relatively) well controlled, the impact of a further
lowering on outcome may be small. Taking all these factors
mentioned above into account, one could argue that in
retrospect our study turned out to be underpowered.
A final aspect needs to be mentioned. Although our study
fails to show an improvement in CVD outcome, the support
of the nurse practitioner results in equal and for some risk
factors even better quality of care. Although the study was not
specifically designed to assess cost effectiveness, it seems
attractive to hypothesize that care in the intervention group is
less costly. Indeed, CanPREVENT showed that nurse practi-
tioner care was cost effective.42 The results are therefore
supportive to a view that nurse practitioner care (using strict
guidelines and supervision) can substitute for specialist care.
This is an important notion in view of the increasing incidence
of patients with CKD, and deserves further attention.43,44
In conclusion, in this randomized study of 788 outpatients
with CKD with mean follow-up of 4.6 years, intensive
treatment with the aid of nurse practitioners resulted in
better control of some risk factors, but did not reduce the
incidence of myocardial infarction, ischemic stroke, or CVD
death. Targeting multiple lifestyle changes was ineffective.
MATERIALS AND METHODS
Study design
MASTERPLAN (Multifactorial Approach and Superior Treatment
Efficacy in Renal Patients with the Aid of Nurse practitioners) is
a multi-center randomized controlled trial. Results are reported
according to CONSORT guidelines.45 The research protocol was
approved by the local ethical committees and all participants gave
written informed consent. Rationale and design have been published
elsewhere.16,46 In brief, subjects were recruited from outpatient
nephrology clinics of nine Dutch hospitals that offered a full range
of nephrology treatment including kidney replacement therapy.
Patients were eligible for inclusion when diagnosed with moder-
ate–to-severe CKD (estimated creatinine clearance by the Cock-
croft–Gault equation between 20 and 70 ml/min).
Recruitment began in April 2004 and continued until December
2005.
Randomization to treatment was performed in a 1:1 ratio
stratified by center and kidney transplant status using a Web-based
block randomization module. All patients were subject to identical
guidelines and treatment goals, which were described previously.16
At baseline, information on medical history, physical activity, and
medication use was obtained by questionnaire. Patients under-
went a physical examination and urine and blood samples were
taken. These measurements were repeated annually. Patients were
asked to fill out a questionnaire on quality of life (SF-36 and
EQ-5D) yearly. All laboratory measurements were performed in
local laboratories.
The underlying diagnosis of kidney disease was determined by
the treating physician using available history, clinical course, and
histopathology (if available) and categorized using the ERA-EDTA
(European Renal Association) registration criteria.
In patients with overt proteinuria, protein in urine was assessed
in g per 24 h. However, by design in patients with known
microalbuminuria albumin in urine was measured in mg per 24 h
and protein in g per 24 h was not measured.
To obtain one value for proteinuria in all patients, albumin
values were converted to proteinuria value using the same approach
as applied by Kidney Disease: Improving Global Outcomes (i.e., by
multiplying albumin values by 3/2).39
Both groups received an automated oscillometric BP measure-
ment every 6 months.
In the intervention group, a nurse practitioner, supervised by a
qualified nephrologist, actively pursued lifestyle intervention (physical
activity, nutritional counseling, weight reduction, and smoking
cessation), the use of specified mandatory medication (statin, either
an angiotensin-converting enzyme inhibitor or angiotensin receptor
blocker, active vitamin D (alfacalcidol), and aspirin and the
implementation of current guidelines (Supplementary Table S1 and
S2 online). Modification of therapy was executed to achieve target
values (Supplementary Table S1 online).
The approach and coaching by nurse practitioners has been
described previously.47 In their contacts with patients, nurse
practitioners aimed at pursuing strict adherence to guidelines and
modifying lifestyle by improving self-management by the patient.48
Endpoints
Primary outcome was a composite of myocardial infarction,
ischemic stroke, and CVD mortality. Myocardial infarction
was defined as evident new ischemic changes on an electrocardio-
gram or an established rise and fall pattern of cardiac enzymes.
Ischemic stroke was defined as characteristic clinical symptoms
and evidence of recent cerebral ischemia using an appropriate
imaging technique (computed tomography scan or magnetic
resonance imaging). CVD mortality was defined as death because
of myocardial infarction, ischemic stroke, ruptured abdominal
aneurysm, terminal heart failure, or sudden death. An independent
end point adjudication committee, blinded for group assignment,
reviewed source documentation for all suspected primary end points
and deaths. Secondary end points were vascular interventions, all-
cause mortality, and start of kidney replacement therapy.
Statistical analysis
MASTERPLAN was originally designed to have a statistical power of
80% to detect a relative risk reduction of 50% or more, based on a
two-tailed test with an alpha level of 5% assuming a CVD rate in the
control group of 13.5% in 5 years. Taking into account a loss to
follow-up of 15% at least 740 patients needed to be randomized.16
All analyses were conducted according to the intention-to-treat
principle. Effects of treatment on study end points were estimated as
HRs and their corresponding 95% CIs with the use of unadjusted
Cox proportional-hazard models, involving survival time to the first
relevant end point in any individual patient. Data for patients were
censored at their date of death, date of last visit (those alive at the
end of follow-up), or date when last known to be alive (those with
unknown vital status).
Differences in continuous and dichotomous variables between
the two treatment groups during the follow-up period were
estimated using linear mixed models (generalized estimating
equations).49 For that analysis, interest was in the mean difference
over time in risk factor levels between treatment arms rather than
the pattern of the change. Generalized estimating equation analyses
were performed using on trial measurements with adjustments for
baseline measurements. All P-values were two-sided, and P-values
o0.05 implied statistical significance. No adjustment for multiple
statistical testing was made.50 The homogeneity of treatment effects
across subgroups (none of which were pre-specified) was tested by
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adding interaction terms to the relevant Cox models. All analyses
were performed with the use of SPSS 17.0 (SPSS, Chicago, IL).
An independent data and safety monitoring committee reviewed
the incidence of the primary end point in the two groups at regular
3-month intervals using group sequential analysis.51 The sequential
analysis has been detailed elsewhere.16 The HR and its CI for the
primary end point were adjusted for the cumulative testing and for
the stratification factors.51
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